Belite Bio to Participate in Three Upcoming Investor Conferences
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focusing on degenerative retinal diseases, has announced its participation in three upcoming investor conferences. The executive management team will attend:
1. H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9, 2024, at 9:30 am ET for a fireside chat.
2. 2024 Cantor Global Healthcare Conference in New York on September 18, 2024, at 3:40 pm ET for a corporate presentation.
3. Deutsche Bank Depositary Receipts Virtual Investor Conference on September 25, 2024, at 11:00 am ET for a virtual corporate presentation.
Webcasts of all presentations will be available on Belite Bio's investor relations website and archived for 90 days after each event.
Belite Bio (NASDAQ: BLTE), un'azienda biofarmaceutica in fase clinica che si concentra sulle malattie retiniche degenerative, ha annunciato la sua partecipazione a tre prossime conferenze per investitori. Il team esecutivo parteciperà:
1. La 26ª Conferenza Globale sugli Investimenti di H.C. Wainwright a New York il 9 settembre 2024, alle 9:30 ET per una conversazione informale.
2. Conferenza Globale sulla Salute di Cantor 2024 a New York il 18 settembre 2024, alle 15:40 ET per una presentazione aziendale.
3. Conferenza Virtuale per Investitori sui Certificati di Deposito di Deutsche Bank il 25 settembre 2024, alle 11:00 ET per una presentazione aziendale virtuale.
Tutti i webcast delle presentazioni saranno disponibili sul sito web delle relazioni con gli investitori di Belite Bio e archiviati per 90 giorni dopo ciascun evento.
Belite Bio (NASDAQ: BLTE), una empresa biofarmacéutica en etapa clínica que se centra en las enfermedades retinianas degenerativas, ha anunciado su participación en tres próximas conferencias para inversores. El equipo de gestión ejecutivo asistirá:
1. 26ª Conferencia Anual Global de Inversión de H.C. Wainwright en Nueva York el 9 de septiembre de 2024, a las 9:30 am ET para una charla informal.
2. Conferencia Global de Atención Médica de Cantor 2024 en Nueva York el 18 de septiembre de 2024, a las 3:40 pm ET para una presentación corporativa.
3. Conferencia Virtual de Inversores de Certificados de Depósito de Deutsche Bank el 25 de septiembre de 2024, a las 11:00 am ET para una presentación corporativa virtual.
Las grabaciones de todas las presentaciones estarán disponibles en el sitio web de relaciones con inversores de Belite Bio y estarán archivadas durante 90 días después de cada evento.
Belite Bio (NASDAQ: BLTE)는 퇴행성 망막 질환에 중점을 두고 있는 임상 단계의 생명공학 회사로, 다가오는 투자자 회의에 참여한다고 발표했습니다. 경영진 팀이 참석할 행사:
1. H.C. Wainwright 제26회 글로벌 투자 회의가 2024년 9월 9일 뉴욕에서 오전 9시 30분 ET에 진행되는 대화형 세션입니다.
2. 2024 Cantor 글로벌 헬스케어 회의가 2024년 9월 18일 뉴욕에서 오후 3시 40분 ET에 기업 발표를 진행합니다.
3. Deutsche Bank 예탁증서 가상 투자자 회의가 2024년 9월 25일 오전 11시 ET에 기업 발표를 가상으로 진행합니다.
모든 발표의 웹캐스트는 Belite Bio의 투자자 관계 웹사이트에서 제공되며 각 이벤트 종료 후 90일간 아카이브됩니다.
Belite Bio (NASDAQ: BLTE), une société biopharmaceutique en phase clinique se concentrant sur les maladies rétiniennes dégénératives, a annoncé sa participation à trois prochaines conférences pour investisseurs. L'équipe de direction sera présente :
1. 26ème Conférence Annuelle Mondiale des Investissements de H.C. Wainwright à New York le 9 septembre 2024, à 9h30 ET pour une discussion informelle.
2. Conférence Mondiale des Soins de Santé Cantor 2024 à New York le 18 septembre 2024, à 15h40 ET pour une présentation d'entreprise.
3. Conférence Virtuelle des Investisseurs des Certificats de Dépôt de Deutsche Bank le 25 septembre 2024, à 11h00 ET pour une présentation d'entreprise virtuelle.
Les webcasts de toutes les présentations seront disponibles sur le site des relations investisseurs de Belite Bio et archivés pendant 90 jours après chaque événement.
Belite Bio (NASDAQ: BLTE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf degenerative Netzhauterkrankungen konzentriert, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen angekündigt. Das Führungsteam wird teilnehmen:
1. 26. jährliche globale Investorenkonferenz von H.C. Wainwright in New York am 9. September 2024 um 9:30 Uhr ET für ein informelles Gespräch.
2. 2024 Cantor globale Gesundheitskonferenz in New York am 18. September 2024 um 15:40 Uhr ET für eine Unternehmenspräsentation.
3. Virtuelle Investorenkonferenz der Deutsche Bank für Depotzertifikate am 25. September 2024 um 11:00 Uhr ET für eine virtuelle Unternehmenspräsentation.
Die Webcasts aller Präsentationen sind auf der Investor-Relations-Website von Belite Bio verfügbar und werden 90 Tage nach jeder Veranstaltung archiviert.
- None.
- None.
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in three upcoming investor conferences. Details for the presentations are as follows:
- H.C. Wainwright 26th Annual Global Investment Conference (New York, New York)
- September 9, 2024, at 9:30 am ET, fireside chat
- 2024 Cantor Global Healthcare Conference (New York, New York)
- September 18, 2024, at 3:40 pm ET, corporate presentation
- Deutsche Bank Depositary Receipts Virtual Investor Conference (Virtual)
- September 25, 2024, at 11:00 am ET, corporate presentation
A webcast of each presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replays will be archived for 90 days following the presentation date.
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases that have significant unmet medical needs such as (i) atrophic age-related macular degeneration (AMD), commonly known as Geographic Atrophy (GA) in advanced dry AMD, and (ii) autosomal recessive Stargardt disease type 1, or STGD1, in addition to specific metabolic diseases. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
FAQ
What investor conferences will Belite Bio (BLTE) attend in September 2024?
When and where is Belite Bio's (BLTE) presentation at the H.C. Wainwright conference?
What type of presentation will Belite Bio (BLTE) give at the Cantor Global Healthcare Conference?
How can investors access Belite Bio's (BLTE) conference presentations?
